Peri-operative Aspirin Continuation Versus Discontinuation

• Status: Terminated
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the continuation (non-discontinuation) of Aspirin during TURBT. Half of participants will continue their usual low-dose Aspirin regimen during TURBT and throughout the perioperative period, while the other half will discontinue Aspirin use ten days prior to surgery (standard recommendation) and restart therapy two weeks post-discharge.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• adults aged 18 years and older with the ability for self-consent,

• referred for elective TURBT,

• receiving low-dose daily Aspirin prophylaxis.

Exclusion Criteria:

• known coagulopathy or abnormal coagulation profile (prothrombin time, partial thromboplastin time, or platelet count),

• receiving other anti-thrombotic, anti-coagulant, or non-steroidal anti-inflammatory medication (NSAIDs),

• pregnancy.